Now Playing
Opinion|Videos|December 7, 2023
Current Treatment Landscape for KRASG12C-Mutated NSCLC
Author(s)Narjust Florez, MD
Narjust Florez, MD, discusses KRAS G12C mutated non-small cell lung cancer, a subset of KRAS mutations which comprises 14% of NSCLC cases.
Advertisement
Episodes in this series
Advertisement
Related to this article
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Matthew Lee, MD, discusses the first clinical data for BG-C477, a CEACAM5-targeting ADC, in advanced NSCLC.
Matthew Lee, MD, shares his key takeaway from the first disclosure of BG-C477 data in advanced NSCLC.
Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.
In the real-world CEMI-LUNG study, first-line cemiplimab produced survival and response outcomes consistent with the pivotal EMPOWER-Lung 1 trial.
Data from the phase 3 OptiTROP-Lung06 trial may support sacituzumab tirumotecan plus pembrolizumab as a new frontline option for this NSCLC population.
Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?
5